inclusion criteria: 1. willing and able to provide written informed consent prior to performing study procedures (or legally authorized representative able to provide consent on the patient's behalf). 2. age ≥ 18 years 3. a positive severe acute respiratory syndrome coronavirus (sars-cov-2) infection confirmed by polymerase chain reaction (pcr) test or an equivalent test ≤ 3 days before randomization 4. patients with mild to moderate covid-19 experiencing any of the following symptoms: * mild (without shortness of breath or dyspnea): fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms * moderate: any symptom of mild illness, shortness of breath with excursion, clinically suggestive of moderate illness with covid-19, such as respiratory rate ≥ 20 breaths per minute, saturation of oxygen (spo2) \> 93% on room air at sea level, heart rate ≥ 90 beats per minute 5. at low risk for progressing to severe covid-19 and/or hospitalization. 6. adequate organ function at screening as evidenced by: * hemoglobin \> 10.9 g/dl * absolute neutrophil count (anc) \> 1.0 × 10\^9/l * platelets \> 125 × 10\^9/l * alanine aminotransferase (alt) or aspartate aminotransferase (ast) \< 1.25 × upper limit of normal (uln) * creatinine clearance \> 90 ml/min using the cockcroft-gault formula for patients ≥ 18 years of age \[cockcroft 1976\] 7. normal electrocardiogram with qtcf of ≤ 450 ms

inclusion criteria: 1. willing and able to provide written informed consent prior to performing study procedures (or legally authorized representative able to provide consent on the patient's behalf). 2. age ≥ 18 years 3. a positive severe acute respiratory syndrome coronavirus (sars-cov-2) infection confirmed by polymerase chain reaction (pcr) test or an equivalent test ≤ 3 days before randomization 4. patients with mild to moderate covid-19 experiencing any of the following symptoms: * mild (without shortness of breath or dyspnea): fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms * moderate: any symptom of mild illness, shortness of breath with excursion, clinically suggestive of moderate illness with covid-19, such as respiratory rate ≥ 20 breaths per minute, saturation of oxygen (spo2) \> 93% on room air at sea level, heart rate ≥ 90 beats per minute 5. at low risk for progressing to severe covid-19 and/or hospitalization. 6. adequate organ function at screening as evidenced by: * hemoglobin \> 10.9 g/dl * absolute neutrophil count (anc) \> 1.0 × 10\^9/l * platelets \> 125 × 10\^9/l * alanine aminotransferase (alt) or aspartate aminotransferase (ast) \< 1.25 × upper limit of normal (uln) * creatinine clearance \> 90 ml/min using the cockcroft-gault formula for patients ≥ 18 years of age \[cockcroft 1976\] 7. normal electrocardiogram with qtcf of ≤ 450 ms

inclusion criteria: willing and able to provide written informed consent prior to performing study procedures (or legally authorized representative able to provide consent on the patient's behalf). age ≥ 18 years a positive severe acute respiratory syndrome coronavirus (sars-cov-2) infection confirmed by polymerase chain reaction (pcr) test or an equivalent test ≤ 3 days before randomization patients with mild to moderate covid-19 experiencing any of the following symptoms: mild (without shortness of breath or dyspnea): fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms moderate: any symptom of mild illness, shortness of breath with excursion, clinically suggestive of moderate illness with covid-19, such as respiratory rate ≥ 20 breaths per minute, saturation of oxygen (spo2) > 93% on room air at sea level, heart rate ≥ 90 beats per minute at low risk for progressing to severe covid-19 and/or hospitalization. adequate organ function at screening as evidenced by: hemoglobin > 10.9 g/dl absolute neutrophil count (anc) > 1.0 × 10^9/l platelets > 125 × 10^9/l alanine aminotransferase (alt) or aspartate aminotransferase (ast) < 1.25 × upper limit of normal (uln) creatinine clearance > 90 ml/min using the cockcroft-gault formula for patients ≥ 18 years of age [cockcroft 1976] normal electrocardiogram with qtcf of ≤ 450 ms

inclusion criteria: willing and able to provide written informed consent prior to performing study procedures (or legally authorized representative able to provide consent on the patient's behalf). age ≥ 18 years a positive severe acute respiratory syndrome coronavirus (sars-cov-2) infection confirmed by polymerase chain reaction (pcr) test or an equivalent test ≤ 3 days before randomization patients with mild to moderate covid-19 experiencing any of the following symptoms: mild (without shortness of breath or dyspnea): fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms moderate: any symptom of mild illness, shortness of breath with excursion, clinically suggestive of moderate illness with covid-19, such as respiratory rate ≥ 20 breaths per minute, saturation of oxygen (spo2) > 93% on room air at sea level, heart rate ≥ 90 beats per minute at low risk for progressing to severe covid-19 and/or hospitalization. adequate organ function at screening as evidenced by: hemoglobin > 10.9 g/dl absolute neutrophil count (anc) > 1.0 × 10^9/l platelets > 125 × 10^9/l alanine aminotransferase (alt) or aspartate aminotransferase (ast) < 1.25 × upper limit of normal (uln) creatinine clearance > 90 ml/min using the cockcroft-gault formula for patients ≥ 18 years of age [cockcroft 1976] normal electrocardiogram with qtcf of ≤ 450 ms

inclusion criteria: 1. willing and able to provide written informed consent prior to performing study procedures (or legally authorized representative able to provide consent on the patient's behalf). 2. age ≥ 18 years 3. a positive severe acute respiratory syndrome coronavirus (sars-cov-2) infection confirmed by polymerase chain reaction (pcr) test or an equivalent test ≤ 3 days before randomization 4. patients with mild to moderate covid-19 experiencing any of the following symptoms: - mild (without shortness of breath or dyspnea): fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms - moderate: any symptom of mild illness, shortness of breath with excursion, clinically suggestive of moderate illness with covid-19, such as respiratory rate ≥ 20 breaths per minute, saturation of oxygen (spo2) > 93% on room air at sea level, heart rate ≥ 90 beats per minute 5. at low risk for progressing to severe covid-19 and/or hospitalization. 6. adequate organ function at screening as evidenced by: - hemoglobin > 10.9 g/dl - absolute neutrophil count (anc) > 1.0 × 10^9/l - platelets > 125 × 10^9/l - alanine aminotransferase (alt) or aspartate aminotransferase (ast) < 1.25 × upper limit of normal (uln) - creatinine clearance > 90 ml/min using the cockcroft-gault formula for patients ≥ 18 years of age [cockcroft 1976] 7. normal electrocardiogram with qtcf of ≤ 450 ms

inclusion criteria: 1. willing and able to provide written informed consent prior to performing study procedures (or legally authorized representative able to provide consent on the patient's behalf). 2. age ≥ 18 years 3. a positive severe acute respiratory syndrome coronavirus (sars-cov-2) infection confirmed by polymerase chain reaction (pcr) test or an equivalent test ≤ 3 days before randomization 4. patients with mild to moderate covid-19 experiencing any of the following symptoms: - mild (without shortness of breath or dyspnea): fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms - moderate: any symptom of mild illness, shortness of breath with excursion, clinically suggestive of moderate illness with covid-19, such as respiratory rate ≥ 20 breaths per minute, saturation of oxygen (spo2) > 93% on room air at sea level, heart rate ≥ 90 beats per minute 5. at low risk for progressing to severe covid-19 and/or hospitalization. 6. adequate organ function at screening as evidenced by: - hemoglobin > 10.9 g/dl - absolute neutrophil count (anc) > 1.0 × 10^9/l - platelets > 125 × 10^9/l - alanine aminotransferase (alt) or aspartate aminotransferase (ast) < 1.25 × upper limit of normal (uln) - creatinine clearance > 90 ml/min using the cockcroft-gault formula for patients ≥ 18 years of age [cockcroft 1976] 7. normal electrocardiogram with qtcf of ≤ 450 ms

inclusion criteria: 1. willing and able to provide written informed consent prior to performing study procedures (or legally authorized representative able to provide consent on the patient's behalf). 2. age ≥ 18 years 3. a positive severe acute respiratory syndrome coronavirus (sars-cov-2) infection confirmed by polymerase chain reaction (pcr) test or an equivalent test ≤ 3 days before randomization 4. patients with mild to moderate covid-19 experiencing any of the following symptoms: - mild (without shortness of breath or dyspnea): fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms - moderate: any symptom of mild illness, shortness of breath with excursion, clinically suggestive of moderate illness with covid-19, such as respiratory rate ≥ 20 breaths per minute, saturation of oxygen (spo2) > 93% on room air at sea level, heart rate ≥ 90 beats per minute 5. at high risk for progressing to severe covid-19 and/or hospitalization. high risk patients are defined as meeting at least one of the following criteria: - have diabetes - have hypertension - have cancer - body mass index (bmi) ≥ 35 - have chronic kidney disease - are ≥ 65 years of age - are ≥ 55 years of age and have - cardiovascular disease such as hypertension, or - chronic obstructive pulmonary disease/other chronic respiratory disease 6. adequate organ function at screening as evidenced by: - hemoglobin > 10.9 g/dl - absolute neutrophil count (anc) > 1.0 × 10^9/l - platelets > 125 × 10^9/l - alanine aminotransferase (alt) or aspartate aminotransferase (ast) < 1.25 × upper limit of normal (uln) - creatinine clearance > 90 ml/min using the cockcroft-gault formula for patients ≥ 18 years of age [cockcroft 1976] 7. normal electrocardiogram with qtcf of ≤ 450 ms

inclusion criteria: 1. willing and able to provide written informed consent prior to performing study procedures (or legally authorized representative able to provide consent on the patient's behalf). 2. age ≥ 18 years 3. a positive severe acute respiratory syndrome coronavirus (sars-cov-2) infection confirmed by polymerase chain reaction (pcr) test or an equivalent test ≤ 3 days before randomization 4. patients with mild to moderate covid-19 experiencing any of the following symptoms: - mild (without shortness of breath or dyspnea): fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms - moderate: any symptom of mild illness, shortness of breath with excursion, clinically suggestive of moderate illness with covid-19, such as respiratory rate ≥ 20 breaths per minute, saturation of oxygen (spo2) > 93% on room air at sea level, heart rate ≥ 90 beats per minute 5. at high risk for progressing to severe covid-19 and/or hospitalization. high risk patients are defined as meeting at least one of the following criteria: - have diabetes - have hypertension - have cancer - body mass index (bmi) ≥ 35 - have chronic kidney disease - are ≥ 65 years of age - are ≥ 55 years of age and have - cardiovascular disease such as hypertension, or - chronic obstructive pulmonary disease/other chronic respiratory disease 6. adequate organ function at screening as evidenced by: - hemoglobin > 10.9 g/dl - absolute neutrophil count (anc) > 1.0 × 10^9/l - platelets > 125 × 10^9/l - alanine aminotransferase (alt) or aspartate aminotransferase (ast) < 1.25 × upper limit of normal (uln) - creatinine clearance > 90 ml/min using the cockcroft-gault formula for patients ≥ 18 years of age [cockcroft 1976] 7. normal electrocardiogram with qtcf of ≤ 450 ms